Shop All
Psoriatic arthritis (PsA) is a seronegative inflammatory arthritis affecting up to 30% of psoriasis patients, characterized by Th17 immune skewing, elevated IL-17A, IL-22, TNF-alpha, and joint destruction alongside skin plaques. Explore how sea moss fucoidan modulates NF-kB and TNF-alpha production, how its anti-inflammatory omega-3 precursors reduce prostaglandin E2 and leukotriene B4 (key PsA inflammatory mediators), how zinc supports skin barrier integrity relevant to plaque formation, how selenium-dependent glutathione peroxidase protects synovial tissue from oxidative stress, and how prebiotic fiber supports microbiome modulation of the gut-joint axis (dysbiosis is increasingly linked to PsA severity). Critical: PsA is a progressive destructive arthritis requiring rheumatologist supervision - biologics targeting IL-17A (secukinumab), IL-12/23 (ustekinumab), or TNF-alpha are disease-modifying; sea moss is a nutritional complement only.
For the complete science-backed breakdown, including mechanisms, dosing, timing, and safety considerations, read our full guide:
Sea Moss for Psoriatic Arthritis: Fucoidan, TNF-Alpha, and Joint-Skin Inflammation
Key topics covered:
- The specific compounds in sea moss relevant to this condition
- Mechanistic pathways (not just anecdotal claims)
- Evidence-based dosing protocols and timing
- Drug interactions and contraindications
- How to integrate with conventional medical care
- What results are realistic and on what timeline
